跳转至内容
Merck
CN

P3350000

脯氨酸

European Pharmacopoeia (EP) Reference Standard

别名:

L-脯氨酸, ( S )-吡咯烷-2-羧酸

登录 查看组织和合同定价。

选择尺寸

变更视图

关于此项目

经验公式(希尔记法):
C5H9NO2
化学文摘社编号:
分子量:
115.13
UNSPSC Code:
41116107
NACRES:
NA.24
PubChem Substance ID:
MDL number:
Beilstein/REAXYS Number:
80810
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助


grade

pharmaceutical primary standard

API family

proline

manufacturer/tradename

EDQM

mp

228 °C (dec.) (lit.)

application(s)

pharmaceutical (small molecule)

format

neat

storage temp.

2-8°C

SMILES string

OC(=O)[C@@H]1CCCN1

InChI

1S/C5H9NO2/c7-5(8)4-2-1-3-6-4/h4,6H,1-3H2,(H,7,8)/t4-/m0/s1

InChI key

ONIBWKKTOPOVIA-BYPYZUCNSA-N

General description

本品按现行药典规定交付。所有为支持本产品而提供的信息,包括SDS和任何产品信息单均由药典颁发机构制定并发布。如需进一步信息和支持,请访问现行药典网站。

Application

脯氨酸EP 参考标准品设计用于欧洲药典规定的实验室测试。

Packaging

本品按照现行药典要求提供。有关当前单位数量,请见EDQM 参考目录

Other Notes

可能适用相应的销售限制条件。


存储类别

13 - Non Combustible Solids

wgk

WGK 1

flash_point_f

Not applicable

flash_point_c

Not applicable



历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our 文件 section.

如需帮助,请联系 客户支持

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库



Roya Hesari et al.
BioImpacts : BI, 10(1), 37-43 (2020-01-29)
Introduction: Transforming growth factor-beta (TGF-β) is known as standard chondrogenic differentiation agent, even though it comes with undesirable side
Antoinette Bugyei-Twum et al.
Cardiovascular diabetology, 13, 89-89 (2014-06-03)
Despite advances in the treatment of heart failure, mortality remains high, particularly in individuals with diabetes. Activated transforming growth factor beta (TGF-β) contributes to the pathogenesis of the fibrotic interstitium observed in diabetic cardiomyopathy. We hypothesized that high glucose enhances
David Saadoun et al.
Annals of the rheumatic diseases, 73(5), 831-837 (2013-04-23)
The standard-of-care treatment of patients with hepatitis C virus (HCV)-mixed cryoglobulinemia (MC) vasculitis includes pegylated interferon α (PegIFN)-α plus ribavirin and/or rituximab. About 30-40% of patients are non-responders or relapsers to such combination. To analyse the safety and efficacy of



全球贸易项目编号

货号GTIN
P335000004061834367741